Send to

Choose Destination
See comment in PubMed Commons below
Psychiatry (Edgmont). 2008 Apr;5(4):25-6.

Generic Penetration of the SSRI Market.

Author information

  • 1Ms. Cascade is Vice President, Strategic Research and Safety, Quintiles Inc., Falls Church, Virginia.


In this article, we investigate the penetration of generic selective serotonin reuptake inhibitors (SSRIs) in the US market and the implications for patient out-of-pocket expense. The data suggest that generic penetration into the SSRI market has grown from approximately nine percent in 2000, the year that the patent for Prozac((R)) expired, to 72 percent in 2007. For December, 2007, the difference in patient out-of-pocket expense for branded vs. generic agents was, on average, $55.42 for patients paying by cash (i.e., they had no prescription drug insurance) and $22.39 for patients with insurance coverage.


SSRI; generic; out-of-pocket expense; prescription; trade

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk